Abstract This special issue is dedicated to spinal and bulbar muscular atrophy (SBMA) and is based on the conference sponsored by the European Neuromuscular Centre (ENMC) held in March 2015. SBMA, also known as Kennedy's disease, is a neurodegenerative disease caused by an expansion of a repeat of the trinucleotide CAG encoding glutamine in the gene encoding androgen receptor (AR). Expansion of polyglutamine in the AR results in selective lower motor neuron degeneration and skeletal muscle atrophy. SBMA belongs to the family of polyglutamine diseases, which also inc l u d e s H u n t i n g t o n 's d i s e a s e , d e n t a t o r u b r a lpallidoluysian atrophy, and spinocerebellar ataxia m a l e s a r e u s u a l l y a s y m p t o m a t i c . I n d e e d , t h e polyglutamine-expanded AR is converted to a neurotoxic species upon binding to androgens. The mechanisms through which androgen binding triggers the disease are under investigation. Although several therapeutic strategies have been proposed to date, there is currently no effective therapy to arrest or delay disease progression in patients.
Introduction
Spinal and bulbar muscular atrophy (SBMA) is an X-linked neuromuscular disease with a prevalence of about 2:100,000 males. The incidence of de novo mutations is not known. SBMA belongs to a family of neurodegenerative diseases caused by CAG expansions, which share specific features such as late onset, an inverse correlation between CAG repeat length and age at onset and a direct correlation with disease severity. Thus, the longer the repeat, the earlier the disease onset and the more severe the symptoms. Moreover, instability of the CAG repeat leads to genetic anticipation, a phenomenon in which the next generation may inherit a longer repeat and a more severe phenotype. However, in SBMA, the correlation between repeat length and disease severity is less evident compared to other polyglutamine diseases, and no evidence of genetic anticipation has been observed. CAG expansions cause degeneration of selected neuronal populations depending on the mutant protein. For example, while the CAG expansion in the AR causes selective lower motor neuron degeneration, in huntingtin, it results in cortico-striatal degeneration, and in ataxin 1 it leads to selective Purkinje cell loss. The basis for this selective neuronal vulnerability is poorly understood. Since the discovery of the mutation causing SBMA in 1991 by Dr. Kenneth Fischbeck and colleagues, our knowledge of the disease pathogenesis has increased remarkably, leading to the development of several therapeutic (SCA) types 1, 2, 3, 6, 7, and 17. Within the family of polyglutamine diseases, SBMA is unique in its gender-specificity, with full disease manifestation restricted to males. Since the disease is ligand (androgen)-dependent, SBMA manifests primarily in males which have high levels of circulating androgens in the serum; feapproaches that are currently being translated into clinical trials. The basis of this special issue on SBMA was the 210th ENMC International Workshop held in March 2015 . During this meeting, clinicians and researchers working in Europe and the USA recognized the need for generation of a European Consortium on SBMA. Participants agreed to contribute a review on the topics discussed at the meeting with the aim of building up a consortium that will actively unify efforts towards a better understanding of disease pathogenesis and therapy development for SBMA. In this special issue, the review papers cover four aspects of SBMA: clinical features, disease mechanisms, in vitro and in vivo models, and clinical trials (Fig. 1) .
The special issue starts with the paper entitled "Spinal and bulbar muscular atrophy overview" by Kenneth Fischbeck (Fischbeck 2015) . This paper summarizes the clinical features of SBMA, describes disease mechanisms involving both loss and gain of AR function, the gender-specificity of SBMA, and the contribution of the AR function, i.e., regulation of expression of androgen-responsive genes, to disease pathogenesis. Importantly, the review describes clinical trials carried out to test the effect of androgen reduction, as well as other recent clinical studies. The review emphasizes the challenges that need to be considered for translating preclinical research into clinical applications. Indeed, since the discovery of the mutation, the field has rapidly advanced and is now ripe for translation into effective therapy for SBMA patients.
The paper by Josef Finsterer and Gianni Sorarù entitled "Onset manifestations of spinal and bulbar muscular atrophy (Kennedy disease)" (Finsterer and Soraru 2015) addresses open questions in the clinical profiling of SBMA. There is indeed a critical need to establish which clinical symptoms better define the onset of disease and whether the age of onset is directly correlated to the length of the CAG expansion when non-motor symptoms are taken into account. A meta-analysis allowed the authors to establish that non-motor symptoms develop before motor symptoms, and when considered in establishing the age of onset, this becomes independent of CAG repeat length. These results imply that non-motor symptoms are important aspects of the disease that should be considered in the estimation of age of onset and disease course. Because the efficacy of treatment may be inversely correlated with disease duration, it is critical to establish unifying criteria to assess disease onset based not only on classical motor symptoms but also on the parameters described in this work.
Following on the same theme related to the clinical aspects of SBMA, Manu Jokela and Bjarne Udd present a paper entitled "Diagnostic clinical, electrodiagnostic and muscle pathology features of spinal and bulbar muscular atrophy" (Jokela and Udd 2015) . Here, clinical, electrodiagnostic, and muscle pathology are reviewed with particular emphasis on the unique features that characterize SBMA with respect to other motor neuron diseases. Several SBMA patients present with sensory neuropathy, with reduced sensory nerve amplitudes, sural nerve abnormalities, and distal primary sensory neuron axonopathy. By electromyography, SBMA patients present signs distinct from amyotrophic lateral sclerosis. Notably, muscle pathology revealed signs of denervation and myopathy associated with very high levels of creatine kinase, which are important features of most SBMA patients. These clinical abnormalities may be useful in the diagnosis of SBMA with respect to other motor neuron diseases, especially amyotrophic lateral sclerosis with which SBMA is often misdiagnosed.
Moving to disease mechanisms and pathogenesis, Carlo Rinaldi, Bilal Malik, and Linda Greensmith author a paper entitled "Targeted molecular therapies for SBMA" . Here the authors describe cellular pathways Fig. 1 Special issue on SBMA. This special issue dedicated to SBMA focuses on four aspects, from clinical features to disease mechanisms, disease models, and clinical trials altered by polyglutamine expansions in the AR, such as transcription regulation, axonal transport, protein quality control, and mitochondria homeostasis. In addition, the authors present several potential therapeutic approaches, including gene silencing, targeting protein quality control, inactivation of the AR and modulation of its function. Because SBMA is a gain of function disease, inhibition of AR expression, or enhancement of AR degradation may be valuable avenues to pursue.
Aria Baniahmad presents a paper entitled "Inhibition of the androgen receptor by anti-androgens in spinobulbular muscle atrophy" (Baniahmad 2015) . In this paper, the author describes the structure and function of the AR, the biological changes occurring upon androgen binding, and how these molecular events contribute to the pathogenesis of SBMA. Emphasis is given to AR antagonists designed to inhibit AR transactivation and induce interaction of AR with corepressors, and compounds such as flutamide and bicalutamide. These drugs have been successfully used in Drosophila and mouse models of SBMA. The results obtained provided evidence that androgen ablation or inhibition of the AR using anti-androgens and AR antagonists reduce SBMA symptoms, indicating therapeutic potential in SBMA. Targeting the disease protein, the polyglutamine-expanded AR, may therefore be a successful avenue to pursue for SBMA therapy development.
An alternative approach to targeting the disease protein is to deliver the mutant AR to protein degradation pathways. Angelo Poletti, Paola Rusmini, Carlo Rinaldi, Linda Greensmith, and colleagues present the review entitled "The role of the protein quality control system in SBMA" (Rusmini et al. 2015) . Here, the authors describe the role of the protein quality control system in the pathogenesis of SBMA. The polyglutamine expansion in the AR results in the accumulation of misfolded protein in neuronal and non-neuronal cells. The authors describe how the polyglutamine expansion alters protein degradation mediated by the proteasome and autophagy, the role of the unfolded protein response (UPR) and the endoplasmic reticulum-associated degradation (ERAD). In addition, the authors describe some recently developed strategies to therapeutically target protein quality control in models of SBMA. Strategies designed to reduce the accumulation of misfolded protein inside vulnerable neurons and non-neuronal cells is associated with beneficial effects in preclinical studies carried out in mouse models of SBMA, thereby providing the rationale for pursuing this strategy for therapy development.
The author of this introductory paper, Maria Pennuto, together with Manuela Basso present a review entitled "In vitro and in vivo modeling of spinal and bulbar muscular atrophy" (Pennuto and Basso 2015) . Here, the authors reviewed the currently available cell and animal models of SBMA, which are used to investigate the pathogenetic pathways underlying SBMA as well as for testing the efficacy of specific drugs in preclinical studies. The authors summarize the advantages and disadvantages of the use of non-neuronal and neuronal cell models and the various mouse models of SBMA that have been generated. Non-neuronal and neuronal cells can give diverse outcomes, especially when AR is overexpressed. Overexpression alters the cellular phenotype not only in vitro (i.e., cultured cells), but also in vivo (i.e., transgenic flies and mice), and this drawback needs to be taken into account when interpreting the data. The introduction of cells derived from patients and the use of knock-in mice may help in addressing whether the observed phenotype is associated with either enhancement of AR expression or polyglutamine expansion.
The final section of this special issue is focused on clinical trial description and development. Mohamed El Mouelhi presented a review entitled "Drug development and challenges for neuromuscular clinical trials" (El Mouelhi 2015) . Here, the author provides an industry perspective and describes the process of drug development, from preclinical and clinical assessment of drug efficacy to distribution of the drug to the market, a process that is very expensive and that can take several years even when successful. Failure of drug development may be caused by several factors including the lack of clear outcome measures, which in the case of neuromuscular diseases such as SBMA is an important factor to consider. This review also discusses the impact of social media and networks on introducing bias among patients. Challenges for neuromuscular diseases, such as SBMA, are described and include the need to introduce placebos in double-blind trials, duration of the trial itself, and route of drug administration.
An overview on past and ongoing clinical trials on SBMA is presented by Patrick Weydt, Davide Pareyson, and colleagues in the review entitled "Clinical trials in spinal and bulbar muscular atrophy -past, present and future" (Weydt et al. 2015) . The authors describe past trials involving the use of anti-androgens, such as leuprorelin and dutasteride, a more recent trial involving the use of beta-agonist, clenbuterol, and exercise (see below). In addition, an ongoing clinical trial by Novartis (ClinicalTrials.gov identifier NCT02024932) due for completion in 2016 is discussed. These clinical trials show promising effects of targeting the disease protein by reducing interaction with its natural ligands, testosterone, and dihydrotestosterone, or targeting skeletal muscle with the use of anabolic agents, such as clenbuterol, and physical exercise. Muscle is indeed now emerging as a primary target of polyglutamine-expanded AR toxicity and, as such, a valuable therapeutic target for SBMA.
A non-pharmacologic approach has been undertaken by Julia Rebecka Dahlqvist and John Vissing, who presented a review entitled "Exercise therapy in spinobulbar muscular atrophy and other neuromuscular disorders" (Dahlqvist and Vissing 2015) . Here, the authors review the results obtained in clinical trials to test the efficacy of physical training in SBMA and other neuromuscular diseases, such as spinal muscular atrophy and amyotrophic lateral sclerosis, and myopathies associated with muscle weakness and wasting. In SBMA, endurance exercise was tested and the results of this trial are carefully reviewed. Further analysis is required to test the effect of different types of exercise.
Finally, Davide Pareyson and colleagues present a paper entitled "Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy" (Pareyson et al. 2016) . Here, the authors discuss the need for the development of a patient registry for SBMA and a biorepository of patient samples. The lack of a disease-modifying therapy for SBMA requires the scientific community to unify the efforts towards development of an effective therapy. To coordinate the work of different research institutions and medical centers, an SBMA registry may facilitate the exchange of information amongst the different centers, the planning and coordination of multicentre clinical trials and epidemiologic studies, as well as the development of standards of care. The same concepts apply in unifying and standardizing the procedures for the collection, storage, and distribution of biological specimens to groups located around the world.
In conclusion, this special issue reinforces the efforts of European investigators towards the establishment of a European consortium dedicated to SBMA. We are grateful to all the authors who submitted reviews and contributed to the revision of manuscripts submitted to this special issue. We are grateful to the editorial office of the Journal of Molecular Neuroscience for their support and for dedicating this issue to SBMA.
